Treatment Adaptation to Surgical Timing in Pediatric Hepatoblastoma: A 19‐Year Single‐Center Experience With Resection and Liver Transplantation

ABSTRACT Background The management of hepatoblastoma (HB) relies on chemotherapy combined with surgery, either liver resection (LR) or liver transplantation (LT), with reported overall survival (OS) of 80%, cardiac toxicity of 6%, nephrotoxicity of 21%, ototoxicity of 32%–46%. In clinical practice, deviations from protocol‐defined chemotherapy are often required to achieve resectability or bridge to transplantation. We aimed to evaluate the impact of treatment adaptation to surgical timing on OS and toxicity in a selected group of patients referred to a transplantation center. Methods We retrospectively analyzed patients with HB treated according to SIOPEL protocols at our center between 2004 and 2022. We collected clinical data, focusing on deviations from protocol‐specified therapy, timing of medical and surgical treatment, OS, treatment‐related toxicities (left ventricular ejection fraction, LVEF< 50%, estimated glomerular filtration rate, eGFR< 90 mL/mL/m 2 , increased hearing threshold of 20–40 dB at 4 kHz). Results Forty‐two patients, median age at diagnosis 1.9 years (IQR 0.7–3.5), 16/42 (38.1%) with metastatic disease, 24/42 (57.1%) with vascular involvement were recorded. Additional chemotherapy beyond protocol indications, due to persistent pulmonary metastases, delayed organ availability, or disease progression was administered to 17/20 (85%) who underwent first‐line LT and 10/22 (45%) who underwent LR ( p = 0.007). Death occurred in 3/20 (15%) versus 7/22 (31.8%) ( p = 0.2) respectively. After median follow‐up of 4.5 years (IQR 1.2–6.2) OS is 32/42 (71.4%); cardiotoxicity developed in 1/42 (2.4%), nephrotoxicity in 8/42 (19%), ototoxicity in 9/42 (21.4%). Conclusions A large proportion of patients with HB require adaptation of protocol‐specified therapy, especially LT candidates. This favors successful management and is not associated with increased toxicity compared to previous reports.

Authors

Institutions

Publication Details

Journal
Pediatric Transplantation
Published
2026-08-27
DOI
https://doi.org/10.1111/petr.70447
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment Adaptation to Surgical Timing in Pediatric Hepatoblastoma: A 19‐Year Single‐Center Experience With Resection and Liver Transplantation

Sandro Sironi, Claudia Pellegrinelli, Lisa Licini, D. Pinelli et al.
Pediatric Transplantation
Hepatocellular Carcinoma Treatment and Prognosis
article

Treatment Adaptation to Surgical Timing in Pediatric Hepatoblastoma: A 19‐Year Single‐Center Experience With Resection and Liver Transplantation

Sandro Sironi, Claudia Pellegrinelli, Lisa Licini, D. Pinelli, Lorenzo D’Antiga, Massimo Provenzi, Clarissa Valle, Laura Cavalleri, Paolo Marra, M. Bravi
article en

Abstract

ABSTRACT Background The management of hepatoblastoma (HB) relies on chemotherapy combined with surgery, either liver resection (LR) or liver transplantation (LT), with reported overall survival (OS) of 80%, cardiac toxicity of 6%, nephrotoxicity of 21%, ototoxicity of 32%–46%. In clinical practice, deviations from protocol‐defined chemotherapy are often required to achieve resectability or bridge to transplantation. We aimed to evaluate the impact of treatment adaptation to surgical timing on OS and toxicity in a selected group of patients referred to a transplantation center. Methods We retrospectively analyzed patients with HB treated according to SIOPEL protocols at our center between 2004 and 2022. We collected clinical data, focusing on deviations from protocol‐specified therapy, timing of medical and surgical treatment, OS, treatment‐related toxicities (left ventricular ejection fraction, LVEF< 50%, estimated glomerular filtration rate, eGFR< 90 mL/mL/m 2 , increased hearing threshold of 20–40 dB at 4 kHz). Results Forty‐two patients, median age at diagnosis 1.9 years (IQR 0.7–3.5), 16/42 (38.1%) with metastatic disease, 24/42 (57.1%) with vascular involvement were recorded. Additional chemotherapy beyond protocol indications, due to persistent pulmonary metastases, delayed organ availability, or disease progression was administered to 17/20 (85%) who underwent first‐line LT and 10/22 (45%) who underwent LR ( p = 0.007). Death occurred in 3/20 (15%) versus 7/22 (31.8%) ( p = 0.2) respectively. After median follow‐up of 4.5 years (IQR 1.2–6.2) OS is 32/42 (71.4%); cardiotoxicity developed in 1/42 (2.4%), nephrotoxicity in 8/42 (19%), ototoxicity in 9/42 (21.4%). Conclusions A large proportion of patients with HB require adaptation of protocol‐specified therapy, especially LT candidates. This favors successful management and is not associated with increased toxicity compared to previous reports.

Pediatric TransplantationVol. 30(9)
Ospedale Papa Giovanni XXIII (IT), University of Milano-Bicocca (IT)
Good health and well-being
Openalex Percentile: Top 12%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.